Australia and New Zealand PCR Systems Market Report and Forecast 2024-2032

Australia and New Zealand PCR Systems Market Outlook

The Australia and New Zealand PCR systems market size is expected to be driven by the rising demand from Asia Pacific PCR systems market, which is likely to grow at a CAGR of 8.4% during the forecast period of 2024-2032. The market growth is likely to be driven by increasing emphasis on preventing pathogen associated infections and technical advancements in the medical research domain.

Australia and New Zealand PCR Systems Market Overview

PCR systems play a critical role in diagnostics and are employed in various applications. It is a fundamental tool in molecular biology, clinical diagnostics, forensic analysis as well as genetic engineering. The PCR systems are witnessing an overall growth in the Asia Pacific region, especially post the COVID-19 pandemic. However, developed nations such as Australia and New Zealand are experiencing key developments, in terms of infrastructure development, rising approvals from regulatory bodies, and new product launches. Such factors are likely to fuel the Australia and New Zealand PCR systems market share in the forecast period.

New Product Launches in the Market

In November 2023, Roche , launched LightCycler® PRO System, a next generation qPCR based on gold standard technology of the LightCycler® Systems. Acting as a bridging gap between translational research and in vitro diagnostics, the new system improves the quality and usability by multiple folds. It is developed to facilitate both research as well as IVD workflows, allowing labs to operate between discovery as well as evaluating the clinical samples of patients. With an aging population on the rise, the introduction of technologies that can be used in multiple application areas, which is expected to drive the Australia and New Zealand PCR systems market growth.

Increased Application Across Various Medical Domains

PCR systems are employed across various medical domains to offer advanced and precise testing, multiple companies are collaborating to bring new products in the market. In March 2023, Stilla Technologies and Atila BioSystems  announced their partnership to co-develop digital PCR kits and assays that can be used in oncology diagnostics. In Australia, the cancer cases are expected to increase, with a significant rise in the population. In 2023, around 165,000 cancer cases were diagnosed in the region. Early detection of cancer can help in better treatment and help in decreasing the mortality rate significantly. As a result, the new digital PCR system can be used to detect the presence of circulating tumor DNA (ctDNA) from liquid biopsy samples taken from patients affected from commonly occurring cancers such as breast, lung, melanoma, prostate, and colorectal cancers.

Surge in Approvals from Regulatory Authorities

The Australia and New Zealand PCR systems market demand is likely to witness significant growth owing to the rise in approvals.In March 2023, BGI Genomics  Multiplex Real-time Fluorescent RT-PCR Kit received the market access qualification to enter the Australian Register of Therapeutic Goods. Used for detecting SARS-CoV-2, Influenza A Virus and Influenza B Virus, the kit can be used to detect all three viruses simultaneously. The approval is major indicator of the ongoing market trend, wherein the regulatory authorities are allowing new testing kits to prevent infections, particularly during the flu season. It also improves the testing efficiency and helps clinicians in modifying their therapeutic regimen based on the patient’s condition.

Australia and New Zealand PCR Systems Market Segmentation

Market Breakup by Product

• Reagents and Consumables

• Instruments

• Software and Services

Market Breakup by Technique

• Conventional PCR

• Real-time PCR

• Digital PCR

• Reverse Transcription PCR

• Hot-start PCR

• Multiplex PCR

• Other PCR Techniques

Market Breakup by Application

• Gene Expression Analysis

• Genetic Sequencing

• Genotyping

• Nucleic Acid Detection

• Nucleic Acid Synthesis

• Standard Validation/Verification

• Diagnostic Applications

• Environmental Applications

• Others

Market Breakup by End User

• Hospitals and Diagnostic Centres

• Healthcare Industries

• Academia and Government Organisations

• Pharma-biotech Companies

• Applied Industries

• Other End Users

Market Breakup by Country

• Australia

• New Zealand

Australia and New Zealand PCR Systems Market Regional Analysis

Australia is likely to lead the PCR systems market share in the coming years owing to the rising investments by government to improve the healthcare and research infrastructure. In addition, the presence of a stringent regulatory framework also fuels the market size.

New Zealand is also experiencing significant PCR systems market growth with a surge in partnerships between prominent companies and emerging start-ups to develop effective solutions for the patients. The healthcare and pharmaceutical sector is witnessing significant expansion in the region, owing to an increase in the aging population and rising investments to prevent infections, mitigate the mortalities associated with chronic diseases and ensuring patient safety.

Australia and New Zealand PCR Systems Market: Competitor Landscape

In April 2023, Thermo Fisher Scientific Inc.,  partnered with ALPCO-GeneProof to bring the TaqPath Menu | GeneProof PCR kits to market. Based on ALPCO GeneProof’s ‘one workflow’ technology, the new product line adds to Thermo Fisher’s exhaustive list of molecular diagnostic assays, and it helps in detecting bloodborne and sexually transmitted infections (STIs). Additional panels for common infections such as transplant and immunocompromised, vector-borne diseases are expected to follow in coming years. The expansion of services with the incorporation of new products is a major market trend that is being adopted by several prominent healthcare companies.

The key features of the Australia and New Zealand PCR systems market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Thermo Fisher Scientific Inc.

• Roche Diagnostics (a division of F. Hoffmann-La Roche Ltd)

• Bio-Rad Laboratories, Inc.

• QIAGEN N.V.

• Agilent Technologies, Inc.

• Abbott Laboratories

• Danaher Corporation

• bioMérieux SA

• PerkinElmer, Inc.

• Fluidigm Corporation

• Eppendorf AG

• Promega Corporation

• Analytik Jena AG (Endress+Hauser Group)

• Illumina, Inc.

• Becton, Dickinson, and Company (BD)

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report